Metabolism - Clinical and Experimental This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Editorial Board
(Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 18, 2023 Category: Biomedical Science Source Type: research

Towards personalized genome-scale modeling of inborn errors of metabolism for systems medicine applications
Inborn errors of metabolism (IEMs) are a group of more than 1000 inherited diseases that are individually rare but have a cumulative global prevalence of 50 per 100,000 births. Recently, it has been recognized that like common diseases, patients with rare diseases can greatly vary in the manifestation and severity of symptoms. Here, we review omics-driven approaches that enable an integrated, holistic view of metabolic phenotypes in IEM patients. We focus on applications of Constraint-based Reconstruction and Analysis (COBRA), a widely used mechanistic systems biology approach, to model the effects of inherited diseases. (...
Source: Metabolism - Clinical and Experimental - November 17, 2023 Category: Biomedical Science Authors: Almut Heinken, Sandra El Kouche, Rosa Maria Rodriguez-Gu éant, Jean-Louis Guéant Tags: Review Source Type: research

Addressing uncertainty about the role of structured lifestyle modification for metabolic surgery patients
There is good evidence that structured lifestyle modification programmes improve health in patients with metabolic and cardiovascular disorders, but there is no specific evidence that they improve outcomes in patients undergoing metabolic or obesity surgery. Despite expert consensus guidelines stating this fact, some healthcare systems still compel patients to participate in a structured lifestyle modification programme prior to metabolic or obesity surgery.There is a well-established need for individualised multidisciplinary dietetic and physical activity care for metabolic and obesity surgery patients, and the benefits o...
Source: Metabolism - Clinical and Experimental - November 17, 2023 Category: Biomedical Science Authors: Enda Murphy, Francis M. Finucane Source Type: research

PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease
Epidemiological evidence links the proprotein convertase subtilisin/kexin 7 (PCSK7) to triglyceride (TG) metabolism. We associated the known PCSK7 gain-of-function non-coding SNP rs236918 with higher levels of plasma apolipoprotein B (apoB) and the loss-of-function coding variant p.Pro777Leu (SNP rs201598301) with lower apoB and TG. Herein, we aimed to unravel the in vivo role of liver PCSK7. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 13, 2023 Category: Biomedical Science Authors: Vatsal Sachan, Ma ïlys Le Dévéhat, Anna Roubtsova, Rachid Essalmani, Jean-Francois Laurendeau, Damien Garçon, Delia Susan-Resiga, Stéphanie Duval, Sahar Mikaeeli, Josée Hamelin, Alexandra Evagelidis, Michael Chong, Guillaume Paré, Elizabeta Chernet Source Type: research

CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease
Podocyte injury is considered as the most important early event contributing to diabetic kidney disease (DKD). Recent findings provide new insights into the roles of lipids and lipid-modulating proteins as key determinants of podocyte function in health and kidney disease. CCDC92, a novel member of coiled-coil domain-containing protein family, was indicated relevant to lipid metabolism, coronary heart disease and type 2 diabetes. However, the expression pattern and role of CCDC92 in the kidney is not clear. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 10, 2023 Category: Biomedical Science Authors: Fuwen Zuo, Youzhao Wang, Xinlei Xu, Ruihao Ding, Wei Tang, Yu Sun, Xiaojie Wang, Yan Zhang, Jichao Wu, Yusheng Xie, Min Liu, Ziying Wang, Fan Yi Source Type: research

Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4
This study was initiated to address the cancer relevance of the results of our earlier work, which had shown that overexpression of KDM2B renders mouse embryonic fibroblasts (MEFs) resistant to oxidative stress by regulating antioxidant mechanisms. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 5, 2023 Category: Biomedical Science Authors: Evangelia Chavdoula, Vollter Anastas, Alessandro La Ferlita, Julian Aldana, Giuseppe Carota, Mariarita Spampinato, Burak Soysal, Ilaria Cosentini, Sameer Parashar, Anuvrat Sircar, Giovanni Nigita, Lalit Sehgal, Michael A. Freitas, Philip N. Tsichlis Source Type: research

Recent research advances in metabolism, clinical and experimental
Metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and non-alcoholic fatty liver disease (NAFLD) – henceforth named metabolic dysfunction-associated steatotic liver disease (MASLD), currently affect a large portion of the general population [1–3]. Due to the complications that they are associated with, namely cardiovascular diseases [CVD] and even mortality, metabolic disorders have an appr eciable impact on productivity and quality of life, and they constitute a challenge to the healthcare systems [4,5]. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 4, 2023 Category: Biomedical Science Authors: Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Laura Valenzuela-Vallejo, Evangelos Axarloglou, Spela Volkansek, Marlene Chakhtoura, Christos S. Mantzoros Tags: Editorial Source Type: research

The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPAR α
Peroxisome proliferator-activated receptor α (PPARα) is a key regulator of hepatic lipid metabolism and therefore a promising therapeutic target against Metabolic-dysfunction Associated Steatotic Liver Diseases (MASLD). However, its expression and activity decrease during disease progression and several of its agonists did not achieve suff icient efficiency in clinical trials with, surprisingly, a lack of steatosis improvement. Here, we identified the Human leukocyte antigen-F Adjacent Transcript 10 (FAT10) as an inhibitor of PPARα lipid metabolic activity during MASLD progression. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 3, 2023 Category: Biomedical Science Authors: Ludivine Clavreul, Lucie Bernard, Alexia K. Cotte, Nathalie Hennuyer, Cyril Bourouh, Claire Devos, Audrey Helleboid, Joel T. Haas, An Verrijken, C éline Gheeraert, Bruno Derudas, Loïc Guille, Julie Chevalier, Jérôme Eeckhoute, Emmanuelle Vallez, Emili Source Type: research

Statin therapy in individuals with intermediate cardiovascular risk
As intermediate cardiovascular risk group accounts for a large part of the total population, determining appropriate cholesterol target in this population is critical. Herein, we investigated the optimal low-density lipoprotein cholesterol (LDL-C) level in individuals with intermediate cardiovascular risk after statin therapy. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 3, 2023 Category: Biomedical Science Authors: Joongmin Kim, Hyeongsoo Kim, Sang Hyun Park, Yura Kang, Kyungdo Han, Sang-Hak Lee Source Type: research

Interplay of lipid metabolism and inflammation in podocyte injury
Podocytes are critical for maintaining permselectivity of the glomerular filtration barrier, and podocyte injury is a major cause of proteinuria in various primary and secondary glomerulopathies. Lipid dysmetabolism and inflammatory activation are the distinctive hallmarks of podocyte injury. Lipid accumulation and lipotoxicity trigger cytoskeletal rearrangement, insulin resistance, mitochondrial oxidative stress, and inflammation. Subsequently, inflammation promotes the progression of glomerulosclerosis and renal fibrosis via multiple pathways. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 2, 2023 Category: Biomedical Science Authors: Zilv Luo, Zhaowei Chen, Jijia Hu, Guohua Ding Tags: Review Source Type: research

Sarcopenia: still in relative definition-penia and severe treatment-penia
Sarcopenia derives from the Greek words “sarx” (i.e., flesh) and “penia” (i.e., deficiency), and denotes the decline in the quantity (i.e., number of motor units) and quality (atrophy of muscle fibers) of the skeletal muscle, together with the decline in muscle strength and physical performance [1,2]. The term sarcopenia was first ly attributed to Dr. Rosenberg, who used it in 1989 to emphasize the importance of the skeletal muscle mass loss occurring with aging [3]. Sarcopenic obesity (SO) refers to the combination of sarcopenia and elevated fat mass and is also gaining increasing interest in research and clinical...
Source: Metabolism - Clinical and Experimental - November 1, 2023 Category: Biomedical Science Authors: Stergios A. Polyzos, Christos S. Mantzoros Tags: Editorial Source Type: research

Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
This narrative review highlights current evidence on non-invasive tests to predict the presence or absence as well as the severity of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition characterized by fat accumulation in the liver that affects 32  % of the world population. The most severe form of MASLD is MASH in which hepatocyte ballooning and inflammation are present together with steatosis; MASH is often associated with liver fibrosis. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - November 1, 2023 Category: Biomedical Science Authors: Lidia Castagneto-Gissey, Stefan R. Bornstein, Geltrude Mingrone Source Type: research

Adiponectin stimulates Sca1+CD34 −-adipocyte precursor cells associated with hyperplastic expansion and beiging of brown and white adipose tissue
The adipocyte hormone adiponectin improves insulin sensitivity and there is an inverse correlation between adiponectin levels and type-2 diabetes risk. Previous research shows that adiponectin remodels the adipose tissue into a more efficient metabolic sink. For instance, mice that overexpress adiponectin show increased capacity for hyperplastic adipose tissue expansion as evident from smaller and metabolically more active white adipocytes. In contrast, the brown adipose tissue (BAT) of these mice looks “whiter” possibly indicating reduced metabolic activity. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - October 31, 2023 Category: Biomedical Science Authors: Marco Bauz á-Thorbrügge, Milica Vujičić, Belén Chanclón, Vilborg Palsdottir, Nicolas J. Pillon, Anna Benrick, Ingrid Wernstedt Asterholm Source Type: research

Epicardial adipose tissue measured from analysis of adipose tissue area using chest CT imaging is the best potential predictor of COVID-19 severity
Computed tomography (CT) imaging is widely used for diagnosing and determining the severity of coronavirus disease 2019 (COVID-19). Chest CT imaging can be used to calculate the epicardial adipose tissue (EAT) and upper abdominal visceral adipose tissue (Abd-VAT) areas. The EAT is the main source of inflammatory cytokines involved in chest inflammatory diseases; thus, the EAT area might be a more useful severity predictor than the Abd-VAT area for COVID-19. However, to the best of our knowledge, there are no large-scale reports that sufficiently consider this issue. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - October 31, 2023 Category: Biomedical Science Authors: Takahiro Fukushima, Tomoki Maetani, Shotaro Chubachi, Naoya Tanabe, Takanori Asakura, Ho Namkoong, Hiromu Tanaka, Takashi Shimada, Shuhei Azekawa, Shiro Otake, Kensuke Nakagawara, Mayuko Watase, Yusuke Shiraishi, Hideki Terai, Mamoru Sasaki, Soichiro Ueda Source Type: research

Adiponectin stimulates Sca1+CD34 − adipocyte precursor cells associated with hyperplastic expansion and beiging of brown and white adipose tissue
The adipocyte hormone adiponectin improves insulin sensitivity and there is an inverse correlation between adiponectin levels and type-2 diabetes risk. Previous research shows that adiponectin remodels the adipose tissue into a more efficient metabolic sink. For instance, mice that overexpress adiponectin show increased capacity for hyperplastic adipose tissue expansion as evident from smaller and metabolically more active white adipocytes. In contrast, the brown adipose tissue (BAT) of these mice looks “whiter” possibly indicating reduced metabolic activity. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - October 31, 2023 Category: Biomedical Science Authors: Marco Bauz á-Thorbrügge, Milica Vujičić, Belén Chanclón, Vilborg Palsdottir, Nicolas J. Pillon, Anna Benrick, Ingrid Wernstedt Asterholm Source Type: research